Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ (State or other jurisdiction of incorporation or organization) Delaware 81-5266334 (I.R.S. Employer Identification No ...

Financial Performance - Total revenues for Q1 2025 were $41.6 million, down 8.6% compared to $45.4 million in Q1 2024[6] - Operating loss was $0.04 million compared to operating income of $0.4 million in the same quarter in the prior year[8] - Net loss was $0.4 million, or $0.05 per basic and diluted share, compared to net loss of $0.2 million, or $0.02 per basic and diluted share, in the prior year quarter[6] - EBITDA for Q1 2025 was $1.0 million compared to $1.4 million in the same period in the prior year[6] - Adjusted EBITDA for Q1 2025 was $1,812,000, down 35.8% from $2,826,000 in Q1 2024[22] - Operating income for Q1 2025 was a loss of $40,000, compared to a profit of $375,000 in Q1 2024[22] - The company reported a net loss of $392,000 for Q1 2025, compared to a net loss of $171,000 in Q1 2024[22] - Adjusted operating margin for Q1 2025 was 1.8%, down from 3.9% in Q1 2024[22] Revenue Breakdown - Customer Care segment revenue was $13.0 million, accounting for 31% of total revenue, with a 4.5% increase year-over-year[6] - Fulfillment & Logistics Services segment revenue was $19.8 million, representing 48% of total revenue, with a 1.8% increase year-over-year[6] - Marketing Services segment revenue decreased by $4.8 million or 35.3% compared to the prior year quarter[6] - Revenue for the Marketing Services segment decreased to $8,782,000, a decline of 35.5% compared to $13,583,000 in the same period last year[23] - Contribution margin for the Fulfillment & Logistics segment was $2,572,000, down from $2,380,000 in the previous year[23] Assets and Liabilities - Total assets decreased to $100,585,000 from $101,782,000, a decline of approximately 1.2% year-over-year[21] - Total current liabilities increased to $36,089,000 from $35,137,000, an increase of approximately 2.7% year-over-year[21] - Cash and cash equivalents decreased to $8,982,000 from $9,934,000, a decline of approximately 9.6% year-over-year[21] - Total stockholders' equity decreased to $21,421,000 from $21,689,000, a decline of approximately 1.2% year-over-year[21] Business Development - Harte Hanks secured several new client engagements across key verticals, including healthcare and technology, indicating new business momentum[3] - The company is committed to expanding lead generation activities and focusing on strategic wins that align with its core capabilities[3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________. Commission file number 1-11889 CEL-SCI CORPORATION Colorado 84-0916344 State or other jurisdiction incorporation (IRS) Employer Ide ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41276 SKYX PLATFORMS CORP. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organiz ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from ____________ to ____________ Commission File Number 001-34471 CHINA PHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 75-1564 ...

[PART I. FINANCIAL INFORMATION](index=4&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Item 1. Unaudited Condensed Consolidated Financial Statements](index=4&type=section&id=Item%201.%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) The unaudited financial statements for Q1 2025 reveal decreased revenue, a reduced net loss, growing stockholders' deficit, and significant liquidity challenges raising going concern doubts [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2025, total assets were $13.7 million, total liabilities $43.9 million, and stockholders' deficit $30.2 million, reflecting increased restricted cash and convertible debentures Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $729 | $764 | | Restricted cash | $10,780 | $8,468 | | **Total assets** | **$13,718** | **$12,878** | | Total current liabilities | $19,794 | $18,982 | | **Total liabilities** | **$43,922** | **$40,587** | | **Total stockholders' deficit** | **($30,204)** | **($27,709)** | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Q1 2025 revenue decreased 26.6% to $5.4 million, while net loss improved to $3.1 million due to significant reductions in operating expenses Statement of Operations Summary (in thousands, except per share data) | Metric | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Revenue | $5,418 | $7,385 | | Total costs and expenses | $7,668 | $11,450 | | Operating loss | ($2,250) | ($4,065) | | **Net loss** | **($3,069)** | **($4,346)** | | Net loss per share | ($0.21) | ($0.46) | [Condensed Consolidated Statements of Cash Flows](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Q1 2025 saw net cash used in operating activities significantly reduced to $115 thousand, with $500 thousand from investing and $1.9 million from financing, leading to a $2.3 million net cash increase Cash Flow Summary (in thousands) | Activity | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | ($115) | ($3,585) | | Net cash provided by investing activities | $500 | $0 | | Net cash provided by financing activities | $1,892 | $3,705 | | **Net increase in cash, cash equivalents and restricted cash** | **$2,277** | **$120** | [Notes to Unaudited Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) Notes detail the company's TPA business, disclose substantial doubt about going concern due to accumulated deficit and negative working capital, and cover financing, revenue, compensation, and subsequent events - The company's operations are conducted through its wholly-owned subsidiaries, primarily providing third-party administrator (TPA) services to self-insured employer groups across the United States[19](index=19&type=chunk) - Management has determined that the company's liquidity condition raises substantial doubt about its ability to continue as a going concern for the next twelve months. The financial statements do not include any adjustments related to this uncertainty[28](index=28&type=chunk) - In January 2025, the company received **$3.0 million** in proceeds from an additional investment related to its Senior Secured Convertible Debentures[54](index=54&type=chunk) - Subsequent to the quarter end, on May 13, 2025, the company appointed a new Chief Operating Officer and issued **730,000 shares** of common stock in a private placement at **$1.00 per share**[84](index=84&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=21&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses a 26.6% revenue decline offset by a 44.6% operating loss reduction, while exploring strategic alternatives amidst critical liquidity concerns and a going concern warning - The company's Board of Directors is exploring strategic alternatives, which may include a strategic investment, a business combination like a merger, or a sale of the Company to maximize shareholder value[91](index=91&type=chunk) - The company's common stock was suspended from trading on Nasdaq and commenced trading on the OTCQX Market effective May 29, 2024[89](index=89&type=chunk) [Results of Operations](index=23&type=section&id=Results%20of%20Operations) Q1 2025 revenue declined 26.6% to $5.4 million due to customer turnover, yet operating loss improved by $1.8 million to $2.3 million through significant expense reductions Comparison of Operations for Three Months Ended March 31 (in thousands) | Line Item | 2025 | 2024 | Change | Change % | | :--- | :--- | :--- | :--- | :--- | | Revenue | $5,418 | $7,385 | $(1,967) | (26.6)% | | Cost of revenue | $3,484 | $4,871 | $(1,387) | (28.5)% | | General and administrative | $2,283 | $3,421 | $(1,138) | (33.3)% | | Operating loss | $(2,250) | $(4,065) | $1,815 | (44.6)% | | Net loss | $(3,069) | $(4,346) | $1,277 | (29.4)% | - The decrease in revenue is primarily due to customer turnover, but the company is adapting its approach and expects new initiatives to drive long-term growth[96](index=96&type=chunk) - The decrease in Sales and Marketing expenses was due to strategic realignment and headcount reduction in Q2 2024[102](index=102&type=chunk) [Liquidity and Capital Resources](index=25&type=section&id=Liquidity%20and%20Capital%20Resources) The company faces critical liquidity with $729 thousand unrestricted cash, a $101.9 million accumulated deficit, and negative working capital, raising substantial doubt about its going concern ability - As of March 31, 2025, the company had an accumulated deficit of approximately **$101.9 million**, unrestricted cash of **$729 thousand**, and negative working capital of **$6.9 million**[107](index=107&type=chunk) - The company has financed its operations primarily through loans, convertible notes, warrants, and equity sales. Recent financing includes receiving **$3.0 million** in January 2025 from an additional investment by JGB[108](index=108&type=chunk)[112](index=112&type=chunk) - Management determined that the company's liquidity condition raises substantial doubt about its ability to continue as a going concern, and it may be forced to scale back operations or divest assets if unable to raise additional capital[116](index=116&type=chunk)[117](index=117&type=chunk) [Cash Flows](index=27&type=section&id=Cash%20Flows) Q1 2025 net cash used in operating activities improved to $115 thousand, with $500 thousand from investing and $1.9 million from financing activities Cash Flow Summary (in thousands) | Activity | Q1 2025 | Q1 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(115) | $(3,585) | | Net cash provided by investing activities | $500 | $0 | | Net cash provided by financing activities | $1,892 | $3,705 | [Item 3. Quantitative and Qualitative Disclosures about Market Risk](index=28&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company identifies market risks from foreign exchange, interest rates, and inflation, none of which are considered material for Q1 2025 - Foreign exchange risk exists due to operations in Israel, but a hypothetical **10% change** in the NIS/USD exchange rate is not expected to have a material impact[125](index=125&type=chunk) - Interest rate risk on cash and cash equivalents of **$729 thousand** is not considered a significant risk by management[126](index=126&type=chunk) - Inflation is not believed to have had a material effect on the business, financial condition, or results of operations during Q1 2025[127](index=127&type=chunk) [Item 4. Controls and Procedures](index=28&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded the company's disclosure controls and procedures were effective as of March 31, 2025, with no material changes in internal control over financial reporting during Q1 2025 - Based on an evaluation as of March 31, 2025, the CEO and CFO concluded that the company's disclosure controls and procedures were effective[128](index=128&type=chunk) - No changes in internal control over financial reporting occurred during the first quarter of 2025 that materially affected, or are reasonably likely to materially affect, internal controls[130](index=130&type=chunk) [PART II. OTHER INFORMATION](index=29&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Item 1A. Risk Factors](index=29&type=section&id=Item%201A.%20Risk%20Factors) Key risks include significant customer concentration in accounts receivable and uncertainties surrounding the costly and potentially disruptive review of strategic alternatives - The company faces risk from customer concentration. As of March 31, 2025, two customers accounted for **35.4%** and **28.1%** of accounts receivable, respectively[134](index=134&type=chunk) - The ongoing review of strategic alternatives is costly, time-consuming, and disruptive. There is no assurance it will lead to a successful transaction or increase shareholder value, and the uncertainty could negatively impact the business and employee retention[136](index=136&type=chunk)[137](index=137&type=chunk) [Item 5. Other Information](index=29&type=section&id=Item%205.%20Other%20Information) On May 13, 2025, the company entered an agreement to sell **730,000 shares** of common stock in a private placement at **$1.00 per share** - On May 13, 2025, the company agreed to issue and sell **730,000 shares** of common stock in a private placement at **$1.00 per share**[138](index=138&type=chunk) [Item 6. Exhibits](index=29&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with Form 10-Q, including the May 13, 2025 Securities Purchase Agreement and Sarbanes-Oxley Act certifications - Key exhibits filed include the May 13, 2025 Securities Purchase Agreement and Sarbanes-Oxley Act certifications by the CEO and CFO[139](index=139&type=chunk) [Signatures](index=31&type=section&id=SIGNATURES) The report was signed and authorized by Damien Lamendola, CEO, and Steve Johnson, CFO, on May 14, 2025 - The report was signed on May 14, 2025, by Damien Lamendola (CEO) and Steve Johnson (CFO)[144](index=144&type=chunk)

Exhibit 99.1 Logistic Properties of the Americas Condensed Consolidated Interim Financial Statements (Unaudited) As of March 31, 2025 and December 31, 2024, and for the three months ended March 31, 2025 and 2024 LOGISTIC PROPERTIES OF THE AMERICAS AND SUBSIDIARIES TABLE OF CONTENTS | Page | | --- | | CONDENSED CONSOLIDATED INTERIM STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE | | | --- | --- | | INCOME (LOSS) | 1 | | CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION | 2 | | CONDENSED CO ...

User Metrics - As of March 31, 2025, the global Monthly Active Users (MAU) decreased by approximately 10.5% year-over-year to around 153 million, primarily due to declines in Korea and the Rest of World[117]. - In Korea, MAU was approximately 24.2 million, down from 27.0 million in the same quarter of 2024, while Japan's MAU increased to 21.9 million from 21.1 million[118][119]. - The Rest of World MAU declined to 107.3 million from 123.2 million, attributed to a government ban on Wattpad and a temporary dip in search traffic due to a security upgrade[120]. Paying Users - The global Monthly Paying Users (MPU) reached 7.4 million with a paying ratio of 4.8%, an increase of 0.3% compared to the previous year[122]. - In Korea, MPU decreased to around 3.4 million with a constant paying ratio of 14.2%, while Japan's MPU increased to 2.2 million with a paying ratio of 10.3%[123]. Revenue Metrics - Revenue is derived from three streams: Paid Content, Advertising, and IP Adaptations, with Paid Content being the primary source[129][130]. - Revenue for the three months ended March 31, 2025, was $325,707 thousand, a slight decrease of 0.3% compared to $326,744 thousand in the same period of 2024[141]. - Paid content revenue decreased by 2.5% to $260,226 thousand from $266,855 thousand year-over-year[142]. - Advertising revenue increased by 7.8% to $39.90 million, and IP Adaptations revenue rose by 11.8% to $25.58 million[166]. - Total revenue for the same period was $325.71 million, a slight decrease of 0.3% from $326.74 million in 2024, while revenue on a constant currency basis increased by 5.3% to $343.84 million[166]. Expenses - Marketing expenses include user acquisition costs and loyalty campaigns, which are essential for brand promotion[132]. - General and administrative expenses encompass all operating costs excluding cost of revenue and marketing, including platform maintenance and stock-based compensation[133]. - Marketing expenses increased significantly by $12,065 thousand, or 61.9%, reaching $31,543 thousand for the three months ended March 31, 2025[145]. - General and administrative expenses rose by $18,009 thousand, or 37.0%, totaling $66,702 thousand, driven by increased stock compensation and headcount costs[146]. Profitability - Net loss attributable to WEBTOON Entertainment Inc. was $22,389 thousand for the three months ended March 31, 2025, compared to a net income of $6,192 thousand in the same period of 2024, representing a decline of 461.6%[141]. - For the three months ended March 31, 2025, the company reported a net loss of $21.97 million compared to a net income of $6.23 million in the same period of 2024[158]. - Adjusted EBITDA for Q1 2025 was $4.08 million, down from $22.16 million in Q1 2024, resulting in an adjusted EBITDA margin of 1.3% compared to 6.8% in the prior year[158]. Cash and Financing - As of March 31, 2025, the company had cash and cash equivalents of $550.1 million, which are primarily invested in short-term, highly liquid investments[170]. - The company completed its IPO on June 28, 2024, raising approximately $281.7 million in net proceeds from the sale of 15 million shares at $21.00 per share[167]. - Net cash used in operating activities for Q1 2025 was $18.65 million, compared to net cash provided of $23.86 million in Q1 2024[173]. - The company plans to use its capital for debt repayment, working capital, capital expenditures, and geographic expansion[171]. - The company may seek additional financing for future acquisitions or investments, which could be affected by current market conditions[172]. Other Financial Metrics - Interest income surged by $3,878 thousand, or 314.0%, to $5,113 thousand, primarily due to interest earned on IPO proceeds[147]. - Interest expense was minimal at $2 thousand for the three months ended March 31, 2025, a decrease of 93.9% from $33 thousand in the same period of 2024[148]. - Loss on equity method investments decreased by $483 thousand, or 45.9%, to $569 thousand compared to $1,052 thousand in the prior year[149]. - Other income increased by $4,107 thousand, or 285.8%, to $2,670 thousand, attributed to gains from foreign currency transactions[151]. - Income tax expense decreased by $4,121 thousand, or 61.8%, to $2,547 thousand, reflecting a shift from income to loss before income tax[152]. - The company reported a significant increase in foreign currency effects, contributing $18.13 million to revenue adjustments in Q1 2025[166].

[Business and Financial Highlights](index=1&type=section&id=Business%20and%20Financial%20Highlights) Precigen advanced PRGN-2012 for RRP with FDA priority review (PDUFA August 2025), ending Q1 2025 with $81 million cash, funding operations into 2026 - The company is highly focused on advancing PRGN-2012, which could become the first FDA-approved therapeutic for RRP, with a PDUFA target action date of **August 27, 2025**[3](index=3&type=chunk)[6](index=6&type=chunk) - Precigen and the Recurrent Respiratory Papillomatosis Foundation will host the 2025 International RRP Awareness Day on June 11 to engage with patients, caregivers, and the healthcare community[3](index=3&type=chunk)[4](index=4&type=chunk) Financial Position | Financial Position | Amount ($) | Note | | :--- | :--- | :--- | | Cash, cash equivalents, and investments | $81.0 million | As of March 31, 2025 | | Cash Runway Expectation | Into 2026 | Excludes potential PRGN-2012 revenue | [Clinical Program Updates](index=1&type=section&id=Clinical%20Program%20Updates) Precigen's clinical pipeline is led by PRGN-2012 nearing FDA approval, with other candidates like PRGN-2009 and PRGN-3006 also advancing [PRGN-2012 AdenoVerse Gene Therapy in RRP](index=1&type=section&id=PRGN-2012%20AdenoVerse%20Gene%20Therapy%20in%20RRP) PRGN-2012, an RRP gene therapy, is under FDA priority review (PDUFA August 2025), showing 51% complete response in pivotal study, with 2025 commercial launch preparations underway - The FDA accepted the BLA for PRGN-2012, granted priority review, and set a PDUFA target action date for **August 27, 2025** An advisory committee meeting is not currently planned[6](index=6&type=chunk)[7](index=7&type=chunk) - Pivotal study results showed **51%** of patients (18 of 35) achieved a Complete Response, requiring no surgeries after treatment, with durable responses observed for up to three years[7](index=7&type=chunk)[8](index=8&type=chunk) - **86%** of patients (30 of 35) experienced a decrease in surgical interventions post-treatment, with median surgeries dropping from 4 to 0[15](index=15&type=chunk) - Commercial and manufacturing readiness campaigns are advancing in anticipation of a potential **2025** launch, supported by commercialization partner EVERSANA[6](index=6&type=chunk)[15](index=15&type=chunk) [PRGN-2009 AdenoVerse Gene Therapy in HPV-associated Cancers](index=3&type=section&id=PRGN-2009%20AdenoVerse%20Gene%20Therapy%20in%20HPV-associated%20Cancers) PRGN-2009, an investigational gene therapy for HPV-associated cancers, is undergoing Phase 2 clinical trials in partnership with the NCI - Phase 2 clinical trials are ongoing for recurrent/metastatic cervical cancer and newly diagnosed HPV-associated oropharyngeal cancer in partnership with the NCI[9](index=9&type=chunk) [PRGN-3006 UltraCAR-T in AML and MDS](index=3&type=section&id=PRGN-3006%20UltraCAR-T%20in%20AML%20and%20MDS) PRGN-3006, an autologous CAR-T therapy for AML and MDS, has completed Phase 1b enrollment for AML and received FDA Orphan Drug and Fast Track designations - The company has completed patient enrollment in the Phase 1b trial for PRGN-3006 in AML[10](index=10&type=chunk) - PRGN-3006 has been granted Orphan Drug Designation for AML and Fast Track Designation for relapsed/refractory (r/r) AML by the FDA[10](index=10&type=chunk) [First Quarter 2025 Financial Results](index=3&type=section&id=First%20Quarter%202025%20Financial%20Results) Precigen's Q1 2025 revenues rose 26% to $1.3 million, while R&D decreased 27% and SG&A increased 22%, resulting in a $54.2 million net loss primarily due to warrant liabilities Financial Performance Summary | Metric | Q1 2025 ($) | Q1 2024 ($) | Change (%) | Reason for Change | | :--- | :--- | :--- | :--- | :--- | | Total Revenues | $1.3M | $1.1M | +26% | Increased volume at Exemplar | | R&D Expenses | $10.5M | $14.2M | -27% | Closure of ActoBio operations and asset prioritization | | SG&A Expenses | $12.4M | $10.2M | +22% | PRGN-2012 commercial readiness activities | | Net Loss | $54.2M | $23.7M | +129% | Primarily a $32.5M non-cash change in fair value of warrant liabilities | | Net Loss Per Share | $(0.18) | $(0.10) | +80% | Increased net loss and higher share count | - Total other expense was **$31.6 million**, a significant shift from an income of **$0.6 million** in Q1 2024 This was driven by a **$32.5 million** non-cash increase in the fair value of warrant liabilities due to a higher stock price[14](index=14&type=chunk) [Consolidated Financial Statements](index=5&type=section&id=Consolidated%20Financial%20Statements) Precigen's unaudited consolidated financial statements for Q1 2025 show total assets of $128.8 million, total liabilities of $113.3 million, and a net loss of $54.2 million [Consolidated Balance Sheets](index=5&type=section&id=Consolidated%20Balance%20Sheets) Precigen's balance sheet as of March 31, 2025, shows total assets of $128.8 million and total liabilities of $113.3 million, driven by increased warrant liabilities Balance Sheet Summary | (Amounts in thousands) | March 31, 2025 ($) | December 31, 2024 ($) | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $6,058 | $29,517 | | Short-term investments | $74,184 | $68,393 | | **Total Assets** | **$128,787** | **$145,266** | | **Liabilities & Equity** | | | | Warrant liabilities | $83,018 | $50,537 | | **Total Liabilities** | **$113,329** | **$78,535** | | Total shareholders' (deficit) equity | $(14,060) | $38,513 | [Consolidated Statements of Operations](index=6&type=section&id=Consolidated%20Statements%20of%20Operations) Precigen's Q1 2025 statement of operations shows $1.34 million in revenues, a $22.6 million operating loss, and a $54.2 million net loss due to warrant liabilities Statements of Operations Summary | (Amounts in thousands, except per share data) | Three Months Ended March 31, 2025 ($) | Three Months Ended March 31, 2024 ($) | | :--- | :--- | :--- | | Total revenues | $1,341 | $1,065 | | Total operating expenses | $23,937 | $25,475 | | Operating loss | $(22,596) | $(24,410) | | Change in fair value of warrant liabilities | $(32,481) | $— | | **Net loss** | **$(54,153)** | **$(23,738)** | | Net loss per share, basic and diluted | $(0.18) | $(0.10) |

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q For the transition period from to Commission file number: 001-38293 SCPHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 46-5184075 (State or other jurisdiction of incorporation or organization) 25 Mall Road, Suite 203 01803 Burlington, Massachusetts (Zip Code) (Address of principal executive office) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For ...